Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients

Objectives Dupilumab, an anti-IL-4 receptor monoclonal antibody (mAb), was recently approved for the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP). The main objective of this study was to assess whether previous exposure to biological treatment affected the clinical outcomes...

ver descrição completa

Detalhes bibliográficos

Principais autores:	María Sandra Domínguez-Sosa, María Soledad Cabrera-Ramírez, Miriam del Carmen Marrero-Ramos, Delia Dávila-Quintana, Carlos Cabrera-López, Heleia González Cuervo, Jesús Javier Benítez del Rosario, Teresa Carrillo-Díaz
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2024-12-01
coleção:	Annals of Medicine
Assuntos:	Chronic rhinosinusitis nasal polyps dupilumab monoclonal antibody perennial allergen sensitization
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/07853890.2024.2411018
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!